The Last Milligram Is the Hardest: What Hyperbolic Tapering Teaches Us About Stopping Antidepressants

Most people — patients and prescribers alike — assume that the hard part of coming off an antidepressant is the beginning. Cut the big dose, and the small dose left at the end should be a formality. The pharmacology says the opposite. The closer you get to zero, the more carefully you often have to move. Understanding why is the heart of what's called hyperbolic tapering, and it reframes a question many patients have quietly carried for years: Was that really my depression coming back, or was it something the medication itself set in motion?

This post draws on a clinical education talk by Anders Sørensen, PhD, on stopping antidepressants, along with the receptor-occupancy research that underpins it (notably work by Mark Horowitz and David Taylor, and Sørensen and colleagues' 2022 systematic review). My goal here is to translate the science into something usable — for people thinking about discontinuing, and for clinicians who want a clearer mental model than "halve it and see."

A mismatch hiding in plain sight

Start with how antidepressants are studied versus how they're actually used. The trials that win regulatory approval typically run eight to twelve weeks. Real-world use looks nothing like that: in the United States, the median duration of antidepressant treatment is roughly five years. A 2025 analysis in the American Journal of Medicine put the contrast starkly — most trials lasted twelve weeks or less, and almost none monitored what happened when people stopped, included a taper protocol, or reported outcomes after treatment ended.

That gap matters because the physiological process behind withdrawal develops gradually, over months and years. The longer someone has taken a medication, the larger the share who report difficulty stopping — and the more severe that difficulty tends to be. Among people who stop abruptly or taper quickly, roughly half describe withdrawal symptoms, and of those, about half again rate them as severe. Crucially, there is still no reliable way to predict in advance who will sail through and who will struggle. Some people genuinely can stop with little trouble. Others experience real functional decline. We don't yet know who is who, which is exactly why a careful, individualized approach is the safe default rather than the exception.

Dependence is not addiction

To make sense of withdrawal, it helps to be precise about a word that gets misused: dependence. When a brain is exposed to a serotonergic drug over time, it adapts. Antidepressants mostly work by blocking reuptake transporters, leaving more neurotransmitter in the synapse. The brain, seeking equilibrium, responds by down-regulating — adjusting receptor sensitivity and number to compensate. A new homeostatic set point is established around the drug's presence.

This adapted state is physical dependence: a normal, expected adaptation defined by a withdrawal syndrome that appears if the drug is stopped or reduced too quickly. It is not addiction, which involves compulsive use and craving. A person taking an antidepressant exactly as prescribed can be physically dependent without being addicted in any meaningful sense — just as someone on a beta-blocker or a steroid can be.

The consequence is this: when the drug level drops faster than the brain can re-adapt, there's a mismatch between what the system expects and what it's getting. That mismatch is the withdrawal state. The symptoms it produces — low mood, anxiety, inner restlessness, sleep disruption — can look almost identical to the original condition. But they reflect a nervous system recalibrating, not an illness returning.

Why the curve bends: receptor occupancy and the hyperbola

Here is the pharmacological insight that changes everything. The relationship between dose (milligrams in the tablet) and effect (how many target receptors are actually occupied) is not a straight line. It's a hyperbola — a curve that rises steeply at first and then flattens.

The numbers are striking. For sertraline, a 25 mg dose already occupies about 65% of the relevant transporters; pushing all the way up to 200 mg only reaches around 83%. Escitalopram occupies roughly 60% of receptors at just 2.5 mg. For most antidepressants, the dose that produces half the maximum effect — the ED50 — is remarkably low: around 3.4 mg for citalopram, 2.7 mg for fluoxetine, 5 mg for paroxetine. A dose that looks trivially small on a prescription pad can still be doing the great majority of the work in the brain.

Read that curve from right to left, the way a taper actually moves, and the implication is clear. At high doses, cutting a fixed number of milligrams barely changes occupancy — that part of the dose has little biological effect, so it usually comes off without trouble. But near the bottom of the curve, where it's steepest, the same milligram cut produces a much larger drop in receptor occupancy. The body reacts to the change in effect, not to the number on the tablet. So a reduction that felt identical to all the previous ones can suddenly hit far harder. That's not the illness breaking through; it's the geometry of the curve.

One important caveat from the underlying data: there's no single "true" occupancy at any given dose. These curves come from group averages, and individual variation is substantial. The practical takeaway is to navigate by the shape of the curve and the body's feedback — not to obsess over hitting a precise occupancy percentage that may not even apply to a particular person.

What hyperbolic tapering actually means in practice

If the effect drops off hyperbolically, then dose reductions should too. Rather than subtracting a fixed amount each time, reductions are sized as a percentage of the current dose — so the steps shrink as the dose shrinks. The working principle is reduce and stabilize, reduce and stabilize: make a cut, let the nervous system settle, and use the presence or absence of withdrawal symptoms as the signal for whether and when to go further. Symptoms returning after a reduction usually mean the drug was still doing something — and that smaller steps are needed before the final drop to zero.

This creates an obvious logistical problem. Standard tablets are simply too coarse for the low end of the curve; even quartering a pill can represent a biologically enormous step. The solutions clinicians and patients use include liquid formulations (which allow finer, more precise reductions), compounding pharmacies (precise but variable in availability and cost), and patient-managed methods such as dissolving a tablet in a known volume of water and removing a measured fraction, or counting the beads in a capsule. None of this is fringe improvisation: the UK's Royal College of Psychiatrists now explicitly endorses hyperbolic tapering, with reductions of roughly 10% of the most recent dose and many additional steps taken below the smallest manufactured tablet strength.

A few practical guardrails matter. Consistency is key — giving the body a different dose each day undermines the steady signal it needs to adapt, which is also why skipping doses is a poor substitute for a proper taper. And severe, disabling withdrawal is not something to "push through." It's a signal to slow down, and sometimes to reinstate the previous dose and then taper more gradually. Staying in severe withdrawal too long risks prolonging it, and in some cases the nervous system can become more reactive rather than less — which is why a taper should be patient-led but clinically guided.

The part that isn't pharmacology

Tapering is rarely just a dosing exercise, and this is where integrating psychotherapy into the work earns its place. Once symptoms are brought down to a tolerable level, they often come under what might be called attentional control — they recede into the background when attention is directed outward, the same way the feeling of your clothes or the chair beneath you disappears until it's named. Helping patients work around unhelpful thoughts rather than being pulled around by them — without either ignoring real distress or reflexively over-reassuring after every anxious thought — can meaningfully reduce the secondary suffering that piles on top of the physical process.

And there's an emotional reentry to navigate. These medications affect feeling broadly, not surgically; patients often describe tapering as waking back up to their full emotional range. That can be overwhelming without support, and it's precisely the part people later point to as the most meaningful reason they wanted to come off in the first place.

Why this challenges the maintenance-treatment story

The most provocative implication is about the evidence base itself. The case for long-term "maintenance" antidepressant treatment rests largely on relapse-prevention trials, which conclude that people who keep taking the drug do better than those who stop. But look at how those landmark reviews actually discontinued patients: in one large analysis, participants stopped in fewer than eleven days; in another, over an average of about two and a half weeks; in a third, most of the included studies stopped in less than a week. By any hyperbolic standard, those are abrupt stops.

If you withdraw people that fast, withdrawal symptoms — which mimic relapse — will appear in the discontinuation group. When the people who stopped get worse, that deterioration gets recorded as the illness returning and counted as evidence that the drug "works" long-term. The unsettling possibility is that some unknown portion of what we've called relapse was withdrawal misclassified. Tellingly, when trials specifically test discontinuation strategies, success rates often cluster near 50% — close to the share of people who report withdrawal in the first place — and the arms that pair tapering with psychological support tend to do better than simply stopping the medication.

The honest position is not that all post-discontinuation symptoms are withdrawal. It's that without controlling for withdrawal, we can't cleanly tell the two apart — and almost no trial to date has built in a slow enough taper to do so.

Where this leaves us

The encouraging conclusion buried in all of this is hopeful: if earlier "failed attempts" to stop were actually rapid-taper withdrawal misread as relapse, then far more people may be able to come off their medication successfully than we assumed — and feel more themselves in the process. The path there runs through tapers that are slow, proportional to the curve, guided by the body's feedback, and supported emotionally as much as pharmacologically. Not everyone needs this level of care. But because we still can't predict who does, building the option in from the start is simply good medicine.